Dr. Basile founded Neumedicines in 2003 and is the driving force behind its success. Dr. Basile wrote the original IL-12 technology patent applications and wrote and secured multiple funded peer-reviewed grants and contracts. To date, Dr. Basile has secured over $33 million in non-dilutive government funding for Neumedicines. Dr. Basile received her doctorate in chemistry from Columbia University in inorganic complex-DNA interactions. She then went on to complete postdoctoral studies at Yale University in the department of Molecular Biology and Biochemistry, where she studied protein-DNA interactions of several DNA-binding proteins including HIV-related proteins. Dr. Basile has over 20 years of scientific experience and also holds a doctorate in law from the University of Houston Law Center. She is a member of the State Bar of California and, prior to founding Neumedicines, practiced as an intellectual property attorney for 7 years.

Mr. Cheung is a co-founder of Neumedicines, and currently serves as Director of Finance for the company. He has over 15 years of experience in financial and business administration. Prior to re-joining the company, he worked at the University of Southern California. He received his MBA in Finance from Loyola Marymount University and BS in Accounting from California State University, Long Beach.

Dr. Gallaher is a co-founder of Neumedicines, and currently serves as the Chief Analytics Officer for the company. He was formerly Director of the Proteomic Core Facility, which is part of the USC School of Pharmacy. Dr. Gallaher has over 20 years of scientific experience since receiving his doctorate degree from the University of California at Santa Cruz. His background is in pharmacology, protein sciences, including proteomics, stem cell biology, and bioinformatics. His bioinformatics efforts led to the discovery of HSS1, a novel protein is a suppressor of tumor growth under development at Neumedicines.

As the COO at Neumedicines, Renata Kovalski manages the multi-million dollar HHS/BARDA contract for the development of HemaMax(TM) towards a BLA submission. Previously, in a consultative role, Renata successfully managed a 3-year HHS/BARDA research and development contract (valued at approximately $15 million) through IND submission and FIH clinical trial. Renata has over 17 years of cross-functional drug development, management, and product team leadership experience. Prior to joining Neumedicines, Renata worked at Amgen where she has held numerous positions in senior leadership and product team development within the operations/manufacturing/quality, clinical development, and corporate areas. Her key achievements at Amgen include successful global regulatory submissions and launches of oncology products including Kepivance(R) indicated for oral mucositis in hematologic cancers and Neulasta(R) indicated for febrile neutorpenia. Prior to Amgen, Renata worked at Diagnostic Products Corporation (currently Siemens Medical Solutions Diagnostics). Renata holds an M.B.A. from Pepperdine University and a B.A. from the University of California, Santa Barbara.

Dr. Gluzman-Poltorak joined Neumedicines Inc. in October 2009 and serves as Nonclinical Director. She has more than 10 years of experience in biotechnology senior management, advancing products from early-stage research up to their regulatory approval. Prior to joining Neumedicines Inc., she was Chief Technology Officer at GeneGrafts Ltd. (2005-2009), and Angiogenesis Project Manager at MGVS Ltd. (2000-2004), both Israeli companies developing innovative genetically modified cell therapy products to address a number of vascular, cardiological, and neurological disorders. She has co-authored 15 peer-reviewed articles and holds a number of patents in angiogenesis, oncology, cardiology and neurology. Dr. Gluzman-Poltorak received her Ph.D in Cell Biology and Genetic Engineering from the Biology faculty of the Technion, Haifa, Israel, and MBA from the Industrial Engineering and Management faculty of the Technion, Haifa, Israel.

Mamata Gokhale has over 15 years of Biotech and Pharma experience in clinical development and regulatory sciences. She has managed strategic and operational activities for early and late phase clinical development and the regulatory interactions and filings. She has a Ph.D. in Biochemistry from University of Bombay, India followed by post-doctoral training at Johns Hopkins School of Medicine. As a research scientist at Hopkins, Mamata set up in vitro toxicology laboratory and collaborated with partners including Warner Lambert (now Pfizer), Rhom and Hass and W.R. Grace. Later she transitioned to the FDA as a clinical pharmacology reviewer and contributed to several agency approvals in addition to conducting regulatory research in dermatopharmacokinetics. Mamata started in the industry at Watson Pharmaceuticals, designed and executed bioavailability and bioequivalence studies for 15 ANDAs, ensured readiness for FDA inspections and advised on biopharmaceutics of 3 high barrier products for rhinitis and asthma. Most recently Mamata was at Amgen with responsibilities for establishing the India office that led to accelerating 7 global clinical trials and supported 1 approval. In her additional roles at Amgen, Mamata customized Quality Management System for regulatory affairs and safety, implemented process improvements, developed target product profiles for pipeline products in oncology, cardiovascular and inflammation areas and also negotiated a new indication for a marketed product.

Dr. Lawrence presently serves as the Bioanalytics Director at Neumedicines Inc. Dr. Lawrence has over 15 years of experience in the Pharmaceutical and Biotechnology industries, occupying positions of increasing responsibility at Sanofi Pharmaceuticals, Amgen Inc., Sunesis Pharmaceuticals, and most recently as Director of Clinical Pharmacology at Xencor Inc. During that time Dr. Lawrence successfully advanced 13 small molecules and biologics into clinical trials, optimizing their pharmacological, pharmacodynamic, and pharmacokinetic properties. Dr. Lawrence was awarded his doctorate degree while researching at the Department of Immunology, Cambridge University, UK, and received his degree in Biochemistry from Newcastle University, UK.

Mrs. Tom joined Neumedicines in September 2009 and serves as Director of Quality. She provides quality oversight on contract manufacturing and contract analytical testing of HemaMax-ARS program. She has over 20 years of experience in the biotechnology industry, occupying positions of increasing responsibility at Amgen, Inc. in clinical and commercial product testing laboratories; sample management and release; and NC/CAPA groups. Outside of Amgen, she held positions at Osmetech Diagnostics, Inc. (currently GenMark Diagnostics, Inc.) and Whitby Research, Inc. She holds an M.B.A. from Pepperdine University and a B.A. from University of California, Santa Barbara.